NASDAQ:HRTS Tema Cardiovascular and Metabolics ETF (HRTS) Price, Holdings, & News $30.72 -0.02 (-0.07%) As of 02/21/2025 03:34 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestTrends About Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HRTS alerts:Sign Up Key Stats Today's Range$30.66▼$30.9550-Day Range$28.67▼$30.9152-Week Range$28.56▼$36.03Volume4,589 shsAverage Volume10,264 shsMarket Capitalization$70.66 millionAssets Under Management$70.89 millionDividend Yield1.50%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.Read More… Tema Cardiovascular and Metabolics ETF ExpensesTypeHRTSTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.56%0.51%0.53%Other Expenses0.00%0.57%0.50%0.47%0.53%Total Expense0.99%0.72%0.72%0.67%0.71%Fee Waiver-0.24%-0.72%-0.50%-0.32%-0.56%Net Expense0.75%0.60%0.62%0.60%0.60% Receive HRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Cardiovascular and Metabolics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTS ETF News HeadlinesHRT may help to protect the heartOctober 22, 2024 | dailymail.co.ukInvesting in Real Assets: The Growing Demand and Opportunity with Brompton’s BREA ETFOctober 10, 2024 | theglobeandmail.comWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."February 22, 2025 | Brownstone Research (Ad)Oil Prices Spike Amid Middle East TensionsOctober 8, 2024 | theglobeandmail.comGuardian Capital LP Launches Two New ETFs on CBOE CanadaOctober 8, 2024 | theglobeandmail.comHigh temperatures and factors such as obesity ‘driving global rises in stroke’September 18, 2024 | msn.comSee More Headlines HRTS ETF - Frequently Asked Questions How have HRTS shares performed this year? Tema Cardiovascular and Metabolics ETF's stock was trading at $28.87 on January 1st, 2025. Since then, HRTS stock has increased by 6.4% and is now trading at $30.72. View the best growth stocks for 2025 here. Who are Tema Cardiovascular and Metabolics ETF's major shareholders? Top institutional shareholders of Tema Cardiovascular and Metabolics ETF include Sterling Investment Advisors Ltd. (7.29%). How do I buy shares of Tema Cardiovascular and Metabolics ETF? Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema Cardiovascular and Metabolics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Cardiovascular and Metabolics ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Barrick Gold (GOLD). Fund Details IssuerTema Global Fund NameTema Cardiovascular and Metabolics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:HRTS Inception Date11/20/2023 Fund ManagerDavid Song, Yuri Khodjamirian Previous SymbolNASDAQ:HRTS WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings44 Fund Statistics Assets Under Management$70.89 million Average Daily Volume$0.00 Discount/Premium-0.08% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest1,500 shs Miscellaneous Outstanding Shares2,300,000Beta0.93 Creation Unit10,000 Creation Fee$500.00 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report Top 10 HRTS HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 10.12%UnitedHealth Group (NYSE:UNH)Holding Weight: 6.00%AstraZeneca PLCHolding Weight: 4.13%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.91%Roche (OTCMKTS:RHHBY)Holding Weight: 3.75%Abbott Laboratories (NYSE:ABT)Holding Weight: 3.72%Novo Nordisk A/SHolding Weight: 3.69%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 3.56%Chugai Pharmaceutical Co., Ltd.Holding Weight: 3.31%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 3.15%Full Holdings DetailsHRTS Sector ExposureHRTS Industry Exposure This page (NASDAQ:HRTS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Cardiovascular and Metabolics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.